Financial Daily from THE HINDU group of publications
Tuesday, Mar 30, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Alliances & Joint Ventures


Lupin inks pact with Allergan to market kids' drugs

Our Bureau

Mumbai , March 29

THE paediatric segment will be the focus for the Mumbai-based Lupin Ltd as it intensifies its efforts in the branded generic drugs segment in the US.

Announcing its second tie-up in the paediatric segment in a little more than a month, Lupin on Monday said that it had entered into a marketing alliance with Allergan Inc to market the paediatric version of Zymar, a solution for conjunctivitis in children.

The alliance has been inked between Lupin's wholly owned subsidiary, Lupin Pharmaceuticals Inc and Allergan.

While Lupin would market the paediatric version of Zymar in the US through its 50-odd field-force, Allergan would promote the same drug for adults, Dr Kamal Sharma, Managing Director, told Business Line. Zymar was launched by Allergan in 2003.

Late last month, Lupin had licensed the Suprax trademark from Wyeth, which had been marketing the drug till March 2003.

Also targeting the paediatric segment, Suprax is the brand name for a suspension form of the antibiotic, cefixime.

Suprax is slated for relaunch in the US market under the Lupin label in April this year.

Dr Sharma said that Lupin had done due diligence with regard to the segment to focus on before it entered the branded generics market.

"In the US, as in India, most pharma companies have drugs for adults and an extension for children. There are some companies that look at the children's segment a little more. But we saw that as a gap in the market. The total opportunity that exists in this segment is estimated to be about $8 billion."

He added that the company was looking to "fortify its portfolio" with products from its own research and development department, besides through alliances.

"Both the products that we are promoting in the paediatrics segment are for infection-led diseases. The benefits of focusing on one segment are that doctor detailing can be improved and the field-force can be utilised economically."

Ms Vinita Gupta, President, Lupin Pharmaceuticals Inc, said that the two products being promoted by the company in the branded generics segment have complementary indications.

"This is a part of our strategy to create a position in the paediatric market segment in the US."

On the financial returns that the alliance would bring to the Rs 1,120-crore Lupin, Dr Sharma said that the two branded generic products "would reflect handsomely" on the company's performance.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Tata Power Broadband to spread to Delhi, Bangalore, Pune


DaimlerChrysler's Maybach gets a few calls
KEC completes Iraq project
C-DIT bags Rs 1.25-cr deal
Glenmark declares interim dividend
Reliance concludes $250-m term loan syndication
M&M to raise $100 m
SAIL, Essar move High Court for probe into steel dumping
Bayer sues Dr Reddy's for patent infringement
Strides programme to hone staff skills
Guj Ambuja's CCB converted to equity shares
EID Parry to sell 3 units to group co
Daewoo Commercial acquisition part of global strategy: Ratan Tata
Tata Motors vows to turn Daewoo unit profitable
Groupe Chimique buys 5 pc stake in GFCL
Matrix Labs to merge 4 cos with itself
ACC picks up UTI's stake to become 100% owner of Bargarh
ABL Bio to buy partner's stake in Shantha Marine
Sundram Fasteners buys stake in Upasana Engg
Shri Shri Resorts acquires 19.11 pc in Vivo Bio Tech
ICICI Ventures takes 54 pc in Arvind Brands
Solae plans to set up production unit in India — Launches soy products in tie up with Speedway
Lupin inks pact with Allergan to market kids' drugs
Tata Power willing to put in Rs 10,000 cr in distribution, generation
Balrampur Chini rights issue likely in early May
LG India targets Rs 7,000-cr sales this fiscal
HMT Q3 loss widens



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line